百济神州终止HER2 ADC药物ZW49合作

• Termination of Licensing Agreement for Zanidatamab Zovodotin with BeiGene

Reacquiring BeiGene APAC territory rights for zanidatamab zovodotin marks a key step, granting us sole responsibility in steering its clinical development and exploring potential combination therapies in clinical trials. We are currently pursuing the initiation of a Phase 2 study of zanidatamab zovodotin in combination with a PD-1 inhibitor in subjects with locally advanced (unresectable) or metastatic HER2-overexpressing non-squamous non-small cell lung cancer (NSCLC). This study is expected to recruit patients in   Asia ,   North America   and   Europe .

​

当年， ZW49数据出来了的时候还以为 Zymeworks会直接终止药物开发。